Microsporidia, a Highly Adaptive Organism and Its Host Expansion to Humans

Nirin Seatamanoch¹,², Switt Kongdachalert¹,², Sakone Sunantaraporn², Padet Siriyasatien¹,² and Narisa Brownell¹,²*

¹ Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ² Vector Biology and Vector Borne Disease Research Unit, Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Emerging infectious disease has become the center of attention since the outbreak of COVID-19. For the coronavirus, bats are suspected to be the origin of the pandemic. Consequently, the spotlight has fallen on zoonotic diseases, and the focus now expands to organisms other than viruses. Microsporidia is a single-cell organism that can infect a wide range of hosts such as insects, mammals, and humans. Its pathogenicity differs among species, and host immunological status plays an important role in infectivity and disease severity. Disseminated disease from microsporidiosis can be fatal, especially among patients with a defective immune system. Recently, there were two Trachipleistophora hominis, a microsporidia species which can survive in insects, case reports in Thailand, one patient had disseminated microsporidiosis. This review gathered data of disseminated microsporidiosis and T. hominis infections in humans covering the biological and clinical aspects. There was a total of 22 cases of disseminated microsporidiosis reports worldwide. Ten microsporidia species were identified. Maximum likelihood tree results showed some possible correlations with zoonotic transmissions. For T. hominis, there are currently eight case reports in humans, seven of which had Human Immunodeficiency Virus (HIV) infection. It is observed that risks are higher for the immunocompromised to acquire such infections, however, future studies should look into the entire life cycle, to identify the route of transmission and establish preventive measures, especially among the high-risk groups.

Keywords: microsporidia, Trachipleistophora hominis, zoonosis, opportunistic infection, disseminated microsporidiosis

INTRODUCTION

Microsporidiosis is an emerging infectious disease caused by a eukaryote from phylum Microsporidia. Microsporidians are capable of infecting both humans and animals depending on the species (Didier and Weiss, 2006). For human beings, the most affected population is the immunocompromised (Han and Weiss, 2017). Regarded as a highly successful parasite, microsporidia adaptability to co-live with their host is impressive. Compelling evidence demonstrated that they have undergone massive genome reduction which has resulted in the loss of considerable protein expressions and crucial organelles such as mitochondria (Wadi and Reinke, 2020). The deprivation of the components
essential for survival in general living things was compensated by their remarkable ability to exploit and steal energy and food from their hosts (Barandun et al., 2019). T. hominis is a member of Microsporidia phylum that originated from insects. Currently, few case reports of T. hominis infection in humans have been reported worldwide. The most common organ involvement of T. hominis infection is the muscle, manifesting as myositis (Curry et al., 2005; Sundaram et al., 2019). A case report of T. hominis myositis has been newly reported in southern Thailand (Buppajarntham et al., 2021). A rarer form of the clinical findings is the disseminated disease, with only two cases in the literature until 2021 when a case of disseminated microsporidiosis caused by T. hominis has been recently reported in the South of Thailand (Ledford et al., 1985; Field et al., 1996; Siripaitoon et al., 2021). The patient was immunocompromised suffering from HIV. Therefore, we would like to conduct a review of disseminated microsporidiosis and T. hominis infection in human beings. The findings will provide a deeper insight into microsporidiosis specifically T. hominis infection encompassing clinical and molecular aspects of the disease.

BIOLOGY AND EVOLUTION

Microsporidia is an obligate intracellular eukaryote. It can persist in the environment within the resistant chitin-lined spore. The distinguishing characteristics that segregate them as another unique taxon include polar tube, posterior vacuole, polaroplast, and diploid chromosomes (in some species). The spore size is around 2-4 µm. The protist reproduces by sporogony in the host cell (Mahmud et al., 2017).

Its life cycle consists of merogony and sporogony stages. For merogony, the mature spore germinates the polar tube and uses it as a weapon to enter the host cell during the infective phase. The apparatus pierces through the cell membrane, paving the way for sporoplasm to enter and later on divides (Weiss et al., 2014). A study in Encephalitozoon hellem illustrates that the polar tube will become ejected in a stimulating environment. Polar tube protein 1 (PTP1) on the apparatus binds with the mannose binding proteins (MBP) on the host’s cell surface leading to the formation of a synapse for the entering sporoplasm. Additionally, the microsporidia’s polar tube protein 4 (PTP4) interacts with transferrin receptor 1 (TfR1) on the host’s cell which facilitates the endocytosis for the creation of the final product, parasitophorous vacuole (Han et al., 2017). The following phase is merogony, as sporoplasm proliferates within the vacuole into meronts producing multinucleate plasmodium forms. Eventually, the sporogony phase ensues, the membrane of each meront thickens and then develops into sporonts. The sporonts later divide into sporoblasts and transform into mature spores in the wait for host cell explosion to exit and infect other organisms (Vávra and Lukeš, 2013; Han and Weiss, 2017).

Microsporidia were firstly divided into three types according to their morphology, namely the Metchnikovellidae, the Chytridiopsidae, Hesseidae, and Burkeidae, and the higher Microsporidia. The higher Microsporidia differs from one of the earliest diverging metchnikovellids in that it contains 32 conserved protein families (Mikhailov et al., 2017). However, due to certain overlapping features among groups, reallocation to a different genus for a species is not uncommon (Franzen et al., 2006; Han and Weiss, 2017). The advent of molecular analysis launched a new way to categorize these organisms and facilitated the determination of their similarities and differences among one another and from other organisms. To date, there are roughly 1400 species under nearly 200 genera of microsporidia (Vávra and Lukeš, 2013).

T. hominis was formerly classified in genus Pleistophora. Through the identification of the difference in ultrastructure, it was given a new name. T. hominis is distinctive from Pleistophora in that it lacks sporogonial plasmodium and has characteristic sporophorous vesicle walls (Hollister et al., 1996). Hollister et al. described T. hominis spores measuring at 4.0 x 2.4 µm with a prominent posterior vacuole. The meronts contain few nuclei while the mature spores contain 9-12 coils of polar tube (Chupp et al., 1993; Hollister et al., 1996; Weiss and Vosbrinck, 1998).

Phylogenetic analysis reveals that rozellids (cryptomycotans) are the microsporidia’s closest relative neighboring fungi (Bass et al., 2018). Apart from the correlated genetic links, a number of cryptomycotans possess certain enzymes that allow them to survive without their functioning mitochondria. This suggests that microsporidia might have emerged from these fungi (Timofeev et al., 2020).

The study of small subunit ribosomal RNA (SSU rRNA) of microsporidia revealed a great variation of genome size, ranging from 2.3 to 51.3 million base pairs (Mb) (Heinz et al., 2012; Wadi and Reinke, 2020). The phenomenon was assumed to have stemmed from the parasite’s heavy reliance upon its host resulting in the disposal of less necessary genes. The smallest microsporidia ever identified was Encephalitozoon intestinalis (2.3 Mb) (Corradi et al., 2010). Galindo et al. described a progressive reduction in DNA repair gene in metchnikovellids, a group of microsporidia, supporting a high evolutionary rate (Galindo et al., 2018). Microsporidia are left with substantially fewer functioning proteins subsequent to the extraordinary genome reduction. Reorientation of the ribosomal protein use was observed to make up for such genetic compaction. Furthermore, the lack of crucial energy producing-organelle like mitochondria, first discovered in Trachipleistophora hominis, is secondary to such genome loss as well (Williams et al., 2002; Barandun et al., 2019; Timofeev et al., 2020). Evidence demonstrated that microsporidia stole adenosine triphosphate (ATP) from its host by mitochondrial binding during residing adaptation (Hacker et al., 2014; Galindo et al., 2018). Despite the absence of a great number of proteins, the remains are sufficient for core basic metabolic pathways such as pentose phosphate and glycolysis pathways (Timofeev et al., 2020).

Unlike most microsporidia, T. hominis genome is relatively large consisting of 8.5 Mb. The preservation of their genes facilitated the study of the microsporidia gene reduction process. The detection of a mitochondrial protein
(mitochondrial Hsp70) in a membrane bound organelle in *T. hominis* elucidated its reluctance to lose membrane organelles, confirming the effort for parasitic adjustments (Williams et al., 2002). Additionally, Ferguson et al. has recently found cell-coating in *T. hominis* that assists the microsporidia in glucose utilization at *T. hominis* and host cell interface (Ferguson and Luccoq, 2019).

The reduced genome size of the microsporidia does not directly correlate with the level of evolution as a large number of genes comes from the non-coded repetitive regions known as transposon elements (TEs) (Parisot et al., 2014). RNA inference genes always coexist with TEs, and it is suggested that RNA inference machinery is responsible for the TE activity prevention (Peyretaillade et al., 2015). RNAi machinery has been suggested to have roles in the eukaryotic defense against foreign nucleic acid such as virus, exogenous DNA, transposon, as well as gene integrity preservation. It is also claimed responsibility for drug tolerance and resistance. Due to this observation, it is inferred that expression of TEs could pose threats to the genome integrity in microsporidia in general (Heinz et al., 2012). RNAi machinery is expressed during *T. hominis* infection but is not regarded as the top 5% overall gene expression (Watson et al., 2015). Similarly, the lack of RNAi was observed in highly developed fungi. It was suspected that these organisms possessed a superior mechanism of protection to compensate for such loss (Lax et al., 2020). Further study of the presence TEs might shed light on the chronological evolution of microsporidia.

**HOST SPECIFICITY**

Microsporidia have a diverse host range. The first group of microsporidia was identified 160 years ago in silkworms namely *Nosema bombycis*. The microsporidia caused Pébrine or pepper disease in silkworms which, at the time, was a great threat to the silk industry (Esvaran et al., 2018). Additionally, microsporidia can infect a rather restricted host range. *Nematocida* species can only infect nematodes of *Caenorhabditis* spp. and *Oscheius tipulae*. Of note, in the same host, tissue tropism was observed among few microsporidia as well; some species infect only intestinal cells while another species infects only epithelial cells (Zhang et al., 2016). One of the exceptions is *Enterocytozoon bieneusi*, which can reside in several mammals and avians, inferring having a broad host range. Another factor attributed to the host range expansion might be the immune status. *Annaliia algerae* was originally regarded as a parasite of mosquitoes. However, inoculation of *Annaliia algerae* spores in athymic mice could cause infection in their connective tissue (Trammer et al., 1997). Emerging case reports of *Annaliia algerae* in humans also proved that *Annaliia algerae* host is not limited to mosquitoes (Coyle et al., 2004; Sut rave et al., 2018). Noticeably, all the identified human cases were immunocompromised, therefore, it is assumed that there is a correlation between the poor immunological status and the higher susceptibility. In the efforts to determine the host range, the study of *E. bieneusi* specific ribosomal internal transcribed spacer (ITS) and multilocus sequence typing (MLST) proved achievable (Li et al., 2019a; Li et al., 2019b). Nonetheless, continuing efforts to further unravel the mechanism behind microsporidia host range specification should be made, especially in the concerns of public health issues (Li et al., 2019b). Furthermore, *in vitro* studies demonstrated that some microsporidia could grow in different tissues in a range of temperatures. This might be the explanation of organ tropisms such as cornea (Visvesvara, 2002).

Previous phylogenetic analysis shows that *T. hominis* is close to *Vavraia culicis*. *V. culicis* is a parasite of anopheline and culicine mosquitoes. Despite their morphological differences, it was proved that *T. hominis* could infect mosquitoes under laboratory conditions. The protist is suspected to be transmitted by hematophagous insects similar to *Annaliia algerae* of mosquitoes, which had reports of causing corneal infection and myositis in human beings (Cheney et al., 2000; Sut rave et al., 2018). *T. hominis* can infect larvae of both *Anopheles quadrimaculatus* and *Culex quinquefasciatus* in a laboratory setting. Similar to the infection in human beings, insect microsporidia can bear toxic effects on their hosts: reducing longevity and fertility (Becnel and Andreais, 2014). However, the mentioned research showed that more than half of the infected mosquito larvae survived and matured into adults. The microsporidia were detected in the muscles, hemocoel, and feeding tubes. The postulated *T. hominis* life cycle in a mosquito is shown in Figure 1. Spores taken from the infected mosquitoes caused significant myositis in athymic mice. Furthermore, spores were passively transferred during sugar water meals, even though the number of spores was limited (Weidner et al., 1999; Mathis et al., 2005). This may imply that the mosquitoes may possess specific qualities that allow the parasites to live within their bodies with insignificant deleterious effect. Additionally, Bayesian analysis conducted in 2015 also suggested that *T. hominis* originated as a parasite of insects (Watson et al., 2015).

Other insects of the suspect for *T. hominis* ancestor hosts are the ants and bees. As mentioned, *T. hominis* genome is comparatively larger among other small microsporidia. *E. cuniculi* genome consists of merely 2.9 Mb whereas *T. hominis* genome is almost three times larger (8.5 Mb) (Katinka et al., 2001). As previously described, the factor that contributes to such a phenomenon is the density of the genome. *T. hominis* genome arrangement is substantially less dense, containing much more intergenic spacers, transposons within. Contrastingly, small-sized microsporidia such as *E. hellem*, *E. cuniculi*, and *E. intestinalis* genes are extremely compact and bear little to no space for TEs (Peyretaillade et al., 2015). There are numerous types of TEs, such as non-LTR elements, Helitron, and piggyBac. PiggyBac jumping gene is present in ants and bees. It is also found in *T. hominis* and *Nosema ceranae* (Watson et al., 2015). *N. ceranae* is an obligate microsporidia species in honeybees, which disrupts the physiology of the bee gut (Burnham, 2019). From genetic analysis, the piggyBac element presented in *T. hominis* was dispersed, illustrating the tendency to have been acquired independently rather than vertically. From the phylogenetic analysis, it was assumed that it obtained the
genes via lateral gene transfer (LGT) from hymenopteran insects (Watson et al., 2015). Fish is another suspected reservoir host of *T. hominis* because it is the host for the closely related *Pleistophora ronnea* (Cheney et al., 2000). However, overall, there is still no solid evidence of *T. hominis* natural host.

**MICROSPORIDIA AND HUMANS**

The earliest confirmed microsporidiosis case in a human was caused by the microsporidia of insect, *Annaliia connori* (Margileth et al., 1973; Sprague, 1974; Franzen et al., 2006; Vávra and Lukěš, 2013). Compiled evidence regarding the transmission of the microsporida among the insects entails both horizontal and vertical means. It has been concluded that horizontal transmission can occur by 1. Cannibalistic feeding of the infected host by another host 2. Oral ingestion of contaminated materials (by dissolved dead bodies, feces, or saliva excretion of the infected in the environment), and 3. Skin exposure to the contaminated ovipositor. Two mechanisms are responsible for vertical transmission: transovarial and via the egg surface. Additionally, the mode of transmission differs among species (Becnel and Andreadis, 2014). As for humans, the disease supposedly spreads through fecal-oral, oral-oral routes, and inhalation of infective spores (Li et al., 2019a). Therefore, contact with reservoir hosts, such as mammals, may pose a risk for infection in a susceptible individual. Waterbody close to animal reservoirs can be the source of the resistant spores, which can remain viable for up to one year (Field and Milner, 2015). Microsporidiosis outbreak was reported in Sweden and the identified source was the sandwiches with cheese and pre-washed fresh cucumbers. It

![Figure 1](https://example.com/figure1.png)
was assumed that the water used to wash the cucumbers was contaminated (Decraene et al., 2012). The direct infection from mosquitoes remains unproven as a human who had been blood-fed by a heavily infected *Amcalia algerae* mosquito did not acquire the disease. The current assumption for the route of infection from the mosquitoes is also the consumption of contaminated water as the mosquitoes are aquatic insects (Undeen and Alger, 1976; Sutrave et al., 2018). Another hypothesis suggests that crushing the infected mosquitoes on the bite site allows disease acquisition (Coyle et al., 2004).

Almost 20 species of microsporidia have been known to cause infection in humans (Han and Weiss, 2017; Li et al., 2019b; Han et al., 2021). The most common pathogenic species is *E. bieneusi* accounting for as many as 90% of all cases (Stentiford et al., 2016; Qiu et al., 2019). It was also responsible for the previously mentioned epidemic in Sweden. Apart from the usual route, an interesting report by Smith et al. described three cases of organ recipients from a brain-dead patient with unrecognized microsporidia infection. The donor had intracranial hemorrhage resulting from complications of cranial aneurysms and arteriovenous malformations repair. All recipients suffered from a spectrum of neurological symptoms. *Encephalitozoon cuniculi* was identified via autopsy in one of the three recipients, other transplant centers were notified of the potential donor-derived infection in which prompt diagnosis and treatment were given to the surviving patients (Smith et al., 2017).

*T. hominis* fails to grow in human cells at 37°C in the laboratory (Cheney et al., 2000). This supports that it might have not been well-adapted to live in human beings, which is congruent with the low number of cases in human beings until present. Therefore, it may be inferred that immune deficient patients acquired the parasite after becoming immunologically depressed, and that the infection was not the result of hidden infection. From the gathered information, it is assumed that the insects are the source of infection. From its genetic relatedness with *V. culcis* and hymenopterans, a proposed diagram of *T. hominis* transmission to humans is shown in Figure 2.

### Zoonosis Presumption from Phylogenetic Analysis

The tree analysis of microsporidia which reported to have caused disseminated disease in human beings is displayed in Figure 3. The sequences of the identified microsporidia in other hosts were also included to find clues of zoonotic transmission. For *E. cuniculi*, all the hosts are mammals such as dogs (*Canis familiaris*), and wild boars (*Sus scrofa*). The sequences that are in proximity to *E. cuniculi* obtained from humans are of dogs. *E. cuniculi* infection is prevalent among pets such as dogs, cats, and rabbits, and is considered zoonotic. Genetic analysis of an infected patient in Switzerland revealed an identical genotype of the prevalent species among rabbits in the area (Weber et al., 1997). For *E. hellem*, the majority of the hosts are of bird species and reported cases in humans are adjacent to the sequences from avian, consistent with previous reports (Polonais et al., 2010). *T. hominis* aligns closely to *A. algerae*, which has reports of infection in mosquitoes (*Anopheles stephensi*) and humans. *T. hominis* position illustrated here correlated with the assumption that the protist might have originated from insects.

### Looming Zoonosis Rise

From our review, it might be indicated that mosquitoes, ants, and bees may serve as a vector for microsporidia of different species. Given that these arthropods might have the capacity to transmit microsporidia to humans, other zoonoses carried by these arthropods may also deserve attention. Geographics heavily influence the prevalence of specific vector-borne diseases as climate greatly affects the vector’s population. For tropical regions, the dominating vectors include mosquitoes and sand flies, which are responsible for, for example, malaria and leishmaniasis respectively (Carvalho et al., 2017). *Plasmodium knowlesi* is a common pathogen for simian malarias in humans. Various *Anopheles* species that are regarded as vectors of *P. knowlesi* are reported in a myriad of countries in Southeast Asia. The ability to infect sympatric species may be a factor that has made the infection more widespread (van de Straat et al., 2022). Such a phenomenon might also occur in some particular anopheles-borne microsporidia whereby it could be carried by multiple species that dwell in the same geographical area. Table 1 illustrated the host spectrum of some microsporidia. It is noticeable that a few could be detected in both insects and humans. Apart from cross-species vectors, the case of cross-genus vectors is observed for Leishmania spp. Leishmania parasites were recently reported in Culicoides biting midges apart from the widely known *Phlebotomine* sand flies in various countries, as well as Thailand (Dougall et al., 2011; Sunantaraporn et al., 2021). The cross-genus finding has highlighted the parasite’s adaptability and/or the host’s competence. The circulations of pathogens among animals and humans might be more extensive than previously known. Several factors may be held accountable. The ongoing human invasion of the forests can significantly lead to increased exposure to disease reservoirs and vectors. The patient of the disseminated *T. hominis* case from the South of Thailand was a rubber tree cultivation worker (Siripaitoon et al., 2021). Working in such an environment may have facilitated parasite acquisition. Additionally, it is believed that human activities that result in climate change have greatly contributed to the rise of emerging infectious diseases in various regions around the world (Morand and Lajaunie, 2021; Rupasinghe et al., 2022). To elucidate further, the amount of rainfall can play a crucial part in some insects’ abundance, for instance (Kishimoto-Yamada and Itioka, 2015; Siripaitoon et al., 2021). The risks may be higher due to the possibility of contamination of resistant spores in the environment for microsporidia. Due to deforestation, excessive migration, and climate change, the expansion of these vector-borne diseases is imminent. Contributing factors should be promptly identified to help slow down the process.
CLINICAL PICTURE INCLUDING DISSEMINATED DISEASE IN HUMANS

Microsporidia usually cause asymptomatic or self-resolving infection in healthy individuals (Didier and Weiss, 2006; Han and Weiss, 2017). Sak et al. observed high rates of positive antibodies against microsporidia in asymptomatic persons. In addition, spores were detected in either urine or stool samples in 100% of the participants over the research period. Therefore, it was assumed that the prevalence of microsporidia might be higher than previously estimated in the normal population. Co-infection of multiple microsporidia species was found in a few individuals as well (Sak et al., 2011). By contrast, the clinical manifestations in an immunocompromised host can be markedly severe. It is still of debate whether the disease is a sequela of a hidden infection or newly acquired (Teachey et al., 2004). HIV patients whose CD4+ T cell level is below 100 cells/mm³ are predisposed to the infection (CDC et al.). A meta-analysis in 2018 by Qiu et al. estimated an overall prevalence of *E. bieneusi* in China at 8.1% among AIDS patients (Qiu et al., 2019). Microsporidiosis was also reported in transplant patients who were on immunosuppressants as well as patients who were on chemotherapy (Mahmood et al., 2003; Carlson et al., 2004). Mice models demonstrated immunological reactions against microsporidia infection, which highlighted the importance of innate and adaptive responses. Both responses were claimed crucial for parasite prevention and elimination (Tomazatos et al., 2020). Nonetheless, we are seeing emerging evidence of...

![Figure 2](image-url)
infections among immunocompetent hosts as well (Didier and Weiss, 2011).

A common clinical manifestation in an immune defect host is persistent diarrhea. The parasites enter via the oral route and proliferate in the epithelial intestinal cells, reducing the digestive surface area, which results in diarrhea (Didier and Weiss, 2006). Other forms of infection include keratitis, sinusitis, encephalitis, and myositis. Some major clinical findings are displayed in Table 1. However, the infection can manifest as a disseminated form attacking multiple organs (Didier, 2005). Regardless of the onset of immune deficiency, systemic microsporidiosis affects people of all ages. The first case of disseminated microsporidiosis was confirmed in a four-month-old infant with thymic aplasia (Margileth et al., 1973). From our case review of 22 disseminated microsporidiosis, we found seven cases were of HIV patients, 11 cases were of post-transplant hosts, and one was of an immunocompetent host (Table 2). Suankratay et al. reported a disseminated microsporidiosis case in a 43-year-old male patient.

FIGURE 3 | Maximum likelihood tree of microsporidia that cause disseminated disease in humans and sequences of the same species of other hosts were included. ML tree was constructed in Mega software version X using Kimura-2 parameter model. The sequences included were based on microsporidia species with reports of causing disseminated diseases in humans. Other nucleotide sequences detected in other organisms were included to find links of zoonosis. T. hominis species are closely related to A. algerae which is congruent with previous reports.
with no underlying diseases. The causative agent was *Endoreticulatus* spp. (Suankratay et al., 2012). From our gathered data, the most commonly affected systems in disseminated cases were the urinary system and respiratory system accounting for 64% (15/22 cases) and 59% (14/22 cases), respectively. Other organ involvement included the gastrointestinal system, muscle, central nervous system, skin, eyes, bone marrow, sinus, thyroid, parathyroid glands, and adrenal glands. Furthermore, the mortality rate stands at roughly 50%.

The reported causative agents of disseminated microsporidiosis cases were *Anncaliia algerae*, *Tubulinosema hellem*, *Endoreticulatus* spp., *Encephalitozoon* spp., *Encephalitozoon intestinalis*, *Trachipleistophora hominis*, *Trachipleistophora anthropophthora*, and *Anncaliia connori*. The most common microsporidia species was *E. cuniculi* (7/22 cases). All cases with *E. cuniculi* had urinary system involvement. As opposed to the assumption, the most prevalent *E. bieneusi* has no record of systemic manifestations.

There have been eight case reports of *T. hominis* including two from Thailand by Siripaitoon et al. and Suankratay et al., as demonstrated in Table 3 (Buppajarntham et al., 2021; Siripaitoon et al., 2021). The most reported clinical manifestation for *T. hominis* is myositis (6 out of 8 cases). The second most common presentation is respiratory symptoms (3 out of 8 cases). Four patients had disseminated disease including one with sole myositis but of distant areas (myocardium, skeletal muscles). The causative agent in reports by Chupp et al., Grau et al., and presumably Ledford et al. was modified from *Pleistophora ronneaelei* (*Pleistophora* spp.) to *T. hominis* due to subsequent ultrastructural characteristics discovery (Ledford et al., 1985; Chupp et al., 1993; Grau et al., 1996; Hollister et al., 1996). It was observed that the diagnosis establishment was challenging in some settings due to low awareness. Patient’s immune status plays an important role. Only one out of eight patients had no immune defect, and the pathogen was exclusively restricted to the eyes for the case (Rauz et al., 2004). Unlike some other microsporidia, *T. hominis* likely lacks tissue specificity. One patient with disseminated *T. hominis* also had keratitis. The infectibility in both corneal and stromal cells of *T. hominis* implies that it is not cell-specific (Field et al., 1996; Moshifir et al., 2020). A study by Koudela et al. illustrated that *T. hominis* did not have tissue specificity in severe combined immunodeficient (SCID) mice and simple contamination on conjunctivae and subcutaneous inoculation, which mimicked insect bite, could lead to generalized infection (Koudela et al., 2004).

## DIAGNOSIS

The diagnosis can be achieved by a number of staining techniques, antigen or antibody detection, transmission electron microscopy (TEM), and nucleic analysis (Valenčaková and Sučík, 2020). The gold standard diagnostic method is TEM. The technique allows the identification of the unique ultrastructural features which offers species determination. However, the technique is both laborious and time-consuming. It also requires specialized expertise for characteristic polar tube identification. Staining with modified trichrome and other conventional stains such as Warthin-starry silver is the more approachable method. The organism is thick-walled and contains a mid-line crossing belt as shown in Figure 4. Chemo-fluorescent stains (for example, Uvitec 2B, Calcofluor White) enhance the wall visibility but can be misinterpreted with fungi (Ghosh and Weiss, 2009). For fecal or urine sampling, multiple specimen collection over a time course may increase yields as spore excretion timing differs from one person to another (Sak et al., 2011). One precaution for the staining technique is the misidentification between microsporidia and *Toxoplasma gondii* cyst as they are similar in both appearance and size (Dubey et al., 1998). Due to indistinct clinical features in the immunocompromised of both infections and lower awareness for microsporidiosis, few patients were initially misdiagnosed with toxoplasmosis instead. Request for further specific microsporidia stains is recommended if a patient is diagnosed with toxoplasmosis (Chupp et al., 1993; Teachey et al., 2004; Buppajarntham et al., 2021). Antigen and antibody detection techniques should be used along with other techniques. Unreliability of the antibody-based detection is subject to cross reactions and difficulties in establishing the onset of infection (acute or past infection). Therefore, it is more utilized in the screening for hidden infections of organ donors. Furthermore, species identification is crucial for treatment as the drug of choice...
| No. | Author et al. (Year) | Year | Infectious Agent | Age/Sex | Outcome | Treatment | Clinical Manifestation | Host | CD4+ (cells/mm³) | Country | Organ involvement |
|-----|----------------------|------|------------------|---------|---------|-----------|------------------------|------|-----------------|---------|------------------|
| 1   | (Margileth et al. (1973)) | 1973 | A. connori | 4mo/M | Death | Antibiotic | Diarrhea, vomiting, irritability, lethargy, fever, maculopapular rash with pustules | Hypogammaglobulinemia | N/A | U.S.A. | Myocardium, liver, diaphragm, GI tract |
| 2   | Schwartz et al. (1992) | 1992 | E. hellem | 30/M | Death | N/A | Prostatitis, hematuria, AIDS flank pain | N/A | 32 | U.S.A. | KUB tract, RS tract, conjunctivae |
| 3   | Scaglia et al. (1994) | 1994 | E. hellem | 32/M | N/A | N/A | AIDS | N/A | Italy | Kidneys, lungs, liver |
| 4   | Yachnis et al. (1996) | 1996 | T. anthropophthera | 8/F | Death | Phenobarbital | Seizures, aphasia, diminished consciousness, hallucinations, inability to walk, difficulty breathing | AIDS *** | N/A | U.S.A. | Kidneys, liver, brain, thyroid, parathyroid, heart, pancreas |
| 5   | Field et al. (1996) | 1996 | T. hominis | 34/M | Recovered but died of HIV | Albendazole, sulfadiazine, pyrimethamine | Myalgia, diplopia, lethargy, weight loss, cough, fever, odynophagia | AIDS | N/A | Australia | Skeletal muscle, conjunctivae, nasal sinuses |
| 6   | Gamboa-Dominguez et al. (2003) | 2001 | E. cuniculi | 42/M | Recovered but relapse | Albendazole | Fever, productive cough, thoracic pain, weakness, herniation, diarrhea | Post-KT (terminal GN and hypertension) | N/A | Mexico | Kidneys, GI tract, liver, skin |
| 7   | Mohindra et al. (2002) | 2002 | E. cuniculi | 45/F | Death | Albendazole, Fumagillin eye drops | Bilateral keratoconjunctivitis, allograft tenderness, fever, generalized seizure | Post-KT (Chronic glomerulonephritis) | N/A | Canada | Kidney, lungs, GI tract, conjunctivae, brain |
| 8   | Svedhem et al. (2002) (Case 1) | 2002 | E. intestinalis | 60/M | Death | Albendazole | Nausea, weight loss, diarrhea | AIDS | 200 | Sweden | Lungs, GI tract |
| 9   | Svedhem et al. (2002) (Case 2) | 2002 | E. intestinalis | 39/M | Died from EBV encephalopathy and B-cell lymphoma | Albendazole | Conjunctivitis, rhinitis, sinustitis, fever, diarrhea, cough, Clinical Manifestation | AIDS | N/A | Sweden | Lungs, GI tract, conjunctivae, nose, sinuses |
| 10  | Carlson et al. (2004) | 2004 | Encephalitozoon spp. | 43/M | Death | N/A | Fever, graft tenderness, anuria, diarrhea | Post-pancreas, kidney transplant (T1DM with ESRD) | N/A | U.S.A. | Kidneys, liver, GI tract, heart, brain, diaphragm, kidneys, lungs |
| 11  | Talabani et al. (2010) | 2009 | E. cuniculi | 38/F | Recovery | Albendazole | Fever, cough, abdominal pain, anorexia | Post-KT (ESRD due to IgA nephropathy) | N/A | France | Kidneys, lungs |
| 12  | George et al. (2012) | 2012 | Encephalitozoon spp. | 57/M | Recovery | Albendazole | Pneumonia | Post-KT (ESRD due to DN) | N/A | Australia | Kidneys, lungs |
| 13  | Suankratay et al. (2012) | 2012 | Endoreticulatus spp. | 43/F | Recovered but died of aspiration pneumonia | Albendazole | Difficulty swallowing, weight loss, leg swelling | Immunocompetent | N/A | Thailand | Kidneys, muscle, bone marrow |

(Continued)
| No. | Author Year | Infectious Agent | Age/ Sex | Outcome | Treatment | Clinical Manifestation | Host | CD4+ (cells/ m3) | Country | Organ involvement |
|-----|-------------|-----------------|----------|---------|-----------|------------------------|------|-----------------|---------|------------------|
| 14  | Meissner et al. (2012) | T. acridophagus | 33/F | Death | N/A | Respiratory failure, jaundice, diarrhea, ascites | Post-HSCT (MM) | N/A | U.S.A. | Liver, lungs, skin |
| 15  | Nagpal et al. (2013) | E. cuniculi | 68/F | Recovery | Albendazole | Nonproductive cough, fever, chills | Post-KT due to ESRD (ADPKD) | N/A | U.S.A. | Kidneys, lungs |
| 16  | Boileau et al. (2016) | A. algerae | 49/M | Recovery | Albendazole pyrimethamine TMP-SMX | Fever, limb pain | 190 | Canada | Deltoids, triceps, quadriceps, brain |
| 17  | Smith et al. (2017) (Case 1) | E. cuniculi | N/A (M) | Recovery | Albendazole | Bilateral tremor, light-headedness, blurry vision, headache | Post-liver transplant (HCV cirrhosis and HCC) | N/A | U.S.A. | Kidneys, brain |
| 18  | Smith et al. (2017) (Case 2) | E. cuniculi | N/A (F) | Recovery | Albendazole | Fever, fatigue, pain in wrists and shins, elbows | Manifeseation Post kidney and heart transplant** | N/A | U.S.A. | Kidneys, brain |
| 19  | Smith et al. (2017) (Case 3) | E. cuniculi | N/A (M) | Death | Antimicrobial drugs | Generalized weakness, confusion, fever | Post-KT** | N/A | U.S.A. | Kidneys, brain |
| 20  | Connors et al. (2017) | T. acridophagus | 58/F | Recovered but expired due to CLL | Albendazole | Widespread skin nodules, nonproductive cough | Undergoing chemotherapy conditioning for HSCT | N/A | Canada | Skin, liver, lungs |
| 21  | Anderson et al. (2019) | A. algerae | 60/M | Death | Albendazole itraconazole clindamycin | Poplar rash on lower extremities | Post-pancreas allograft transplant (T1DM) AIDS | N/A | U.S.A. | Kidneys, lungs, finger, tongue, lower extremity |
| 22  | Siripaitoon et al. (2021) | T. hominis | 29/F | Death | Albendazole TPM/SMX clindamycin | Incapacitating myalgias, fever, lethargy | 15 | Thailand | Muscle, bone marrow |

M, Male; G, Female; GI, gastrointestinal; KUB, Kidney, ureter, and bladder; T1DM, Type 1 Diabetes Mellitus; T2DM, Type 2 Diabetes Mellitus; DN, Diabetic nephropathy; GN, glomerulonephritis; HCC, hepatocellular carcinoma; CLL, Chronic Lymphocytic Leukemia; TMP-SMX, Trimethoprim/sulfamethoxazole; ESRD, End stage renal disease; HSCT, hematopoietic stem cell transplantation; ADPKD, Autosomal dominant polycystic kidney disease; MM, Multiple Myeloma; HCV, Hepatitis C Virus; KT, Kidney Transplant; N/A, non-applicable; *ESRD due to T2DM **coronary vasculopathy and calcineurin inhibitor–induced nephropathy *** HIV (congenitally acquired), hemangiopericytoma (metastatic to diaphragm and intestine)

E. cuniculi: Encephalitozoon cuniculi, A. algerae: Anncaliia algerae, T. acridophagus: Tubulinosema acridophagus, Encephalitozoon spp.: Encephalitozoon species, E. intestinalis: Encephalitozoon intestinalis, T. hominis: Trachipleistophora hominis, E. hellem: Encephalitozoon hellem, Endoreticulatus spp.: Endoreticulatus species, T. anthropophthera: Trachipleistophora anthropophthera, A. connori: Anncaliia connori.
varies upon the species and organs affected (CDC et al.). Even though detailed morphology can be examined by TEM, for some close species such as *E. cuniculi* and *E. hellem*, TEM alone might be inadequate. The nucleic acid analysis comes in useful. rRNA of microsporidia contains both conserved and variable genes and thus are used as the target for PCR-based techniques (Ghosh and Weiss, 2009). PCR primers for SSU rRNA for specific species were described by Weiss et al. (Weiss and Vossbrinck, 1998). Additionally, large subunit (LSU), and ITS genes from the rRNA can be used to identify novel species of microsporidia as well.

The majority of specimen types can be directly used for PCR analysis by regular DNA extraction procedure, however, stool samples need mechanical disruption prior to DNA amplification (Weiss and Vossbrinck, 1998; Ghosh and Weiss, 2009).

**TREATMENTS**

The mainstay medication for microsporidiosis is albendazole and fumagillin. Albendazole inhibits β-tubulin which halts the parasite mitosis. Fumagillin targets methionine aminopeptidase.
type 2 (MetAP2), which results in increased lipid incorporation in the parasite membrane and leads to cell breakage and death. The agent also plays a role in RNA synthesis blockade (Anane and Attouchi, 2010). Albendazole covers a narrower spectrum of microsporidia when compared to fumagillin. Despite fumagillin efficacy, its toxicity of bone marrow suppression undermines its attractiveness. Albendazole cannot contain E. bieneusi infection but fortunately, nitazoxanide was proved effective (Saffo and Mirza, 2019). New drug targets have been introduced for treatment, but to date, only meagre data is available for their effectiveness (Han and Weiss, 2018). For intestinal microsporidiosis, albendazole 400 mg orally three times daily for two weeks or twice daily for four weeks is recommended (Mahmud et al., 2017). The main challenge of the treatment of disseminated cases is the poor immunological status of the patients. It is observed in many cases that albendazole use was extended until the patients achieved significant clinical improvement and clinical specimens were free of the parasites. It is also recommended that, in HIV patients, discontinuing the medication should be considered after their CD4+ has reached 100 cells/mm³ while the patients are concurrently taking antiretrovirals to boost their immune system (CDC et al.; Talabani et al., 2010). Additionally, some physicians decided to give a lifelong albendazole prescription to a post kidney transplant patient (George et al., 2012). If the immunological status of the patient cannot be fully restored, the benefits of prolonged albendazole use might outweigh the risks. There is still no indication for chemical prophylaxis against microsporidia, thus maintaining good personal hygiene and consuming fully cooked food might be an optimal solution to lower the infection risks.

Apart from E. bieneusi, albendazole was claimed effective against other microsporidal infections, as well as T. hominis (CDC et al.). Treatment outcomes varied in T. hominis patients. Due to a limited number of cases, it is challenging to determine its efficacy. For HIV patients with T. hominis myositis treated with albendazole, three cases reported improvement (one recovered, but two died of progressive HIV disease). In vitro study of albendazole in mouse myoblast cell line revealed unpromising results. It was observed that the spore stage was unaffected and led to the parasite recovery. The assumption was that T. hominis B-tubulin, a target of albendazole, may differ from other microsporidia (Lafranchi-Tristem et al., 2001). Other medications used were pyrimethamine, bactrim, etc. Pyrimethamine was used in patients that firstly were diagnosed with myositis of Toxoplasma gondii (Chupp et al., 1993; Buppajarntham et al., 2021). The patients who received the pyrimethamine got worse or did not respond to the medication (Chupp et al., 1993; Field et al., 1996; Buppajarntham et al., 2021). The patient who received bactrim and other antimicrobials excluding albendazole reported slight improvement (Ledford et al., 1985). Early treatment before numerous spore formations might provide better results. Similar to other microsporidiosis cases, immune restoration should be of equal importance (CDC et al.).

Microsporidia is a parasite of various hosts. Evidence have shown its potential for zoonotic transmission in which patients with depressed immune are at a higher risk of acquiring the infection. T. hominis should be suspected when the diagnosis of toxoplasmosis is made. Molecular diagnosis may be helpful in such cases. As a highly adaptive parasite, we might see a greater number of cases of microsporidiosis in human beings in the future. The role of the insects as a vector should be further explored for the rise of T. hominis infections in Thailand.

REFERENCES

Anane, S., and Attouchi, H. (2010). Microsporidiosis: Epidemiology, Clinical Data and Therapy. Gastroenterol. Clin. Biol. 34 (8-9), 450–464. doi: 10.1016/j.gcb.2010.07.003

Anderson, N. W., Muehlenbachs, A., Anfi, S., Bruminhent, J., Dezeli, P. J., Razonable, R. R., et al. (2019). A Fatal Case of Disseminated Microsporidiosis Due to Annacalia Algerae in a Renal and Pancreas Allograft Recipient. Open Forum Infect. Dis. 6 (7), ofz285. doi: 10.1093/ofid/ofz285

Barandun, J., Hunziker, M., Vossbrinck, C. R., and Klinge, S. (2019). Evolutionary Compaction and Adaptation Visualized by the Structure of the Dormant Microsporidian Ribosome. Nat. Microbiol. 4 (11), 1796–1804. doi: 10.1038/s41564-019-0154-6

Bass, D., Czech, L., Williams, B. A. P., Berney, C., Dunthorn, M., Mahé, F., et al. (2018). Clarifying the Relationships Between Microsporidia and Cryptonyctoca. J. Eukaryot. Microbiol. 65 (6), 773–782. doi: 10.1111/jem.12519

Becnel, J. J., and Andreadis, T. G. (2014). “Microsporidia in Insects,” in Microsporidia. (USA: John Wiley & Sons, Inc.) 521–570.

Boileau, M., Ferreira, I., Ahmad, I., Lavallée, C., Qvarnstrom, Y., and Dufresne, S. F. (2016). Successful Treatment of Disseminated Annacalia Algerae Microsporidal Infection With Combination Fumagillin and Albendazole. Open Forum Infect. Dis. 3 (3), ofw158. doi: 10.1093/ofid/ofw158

Buppajarntham, A., Atikanukul, T., Putaporntip, C., Jongwutiwes, S., and Suankratay, C. (2021). Myositis Caused by Trachipleistophora Hominis in a Person With Human Immunodeficiency Virus: The First Case in Thailand. Open Forum Infect. Dis. 8 (12), ofab494. doi: 10.1093/ofid/ofab494

Burnham, A. J. (2019). Scientific Advances in Controlling Nosema Ceranae (Microsporidia) Infections in Honey Bees (Apis Mellifera). Front. Vet. Sci. 6 (79), 79. doi: 10.3389/fvets.2019.00079

Carlson, J. R., Li, L., Helton, C. L., Munn, R. J., Wasson, K., Perez, R. V., et al. (2004). Disseminated Microsporidiosis in a Pancreas/Kidney Transplant Recipient. Arch. Pathol. Lab. Med. 128 (3), e41–e43. doi: 10.5858/2004-128-e41-DMIAKT

Carvalho, B. M., Rangel, E. F., and Vale, M. M. (2017). Evaluation of the Impacts of Climate Change on Disease Vectors Through Ecological Niche Modelling. Bull. Entomol. Res. 107 (4), 419–430. doi: 10.1017/s0007485316001097

Boileau, M., Ferreira, I., Ahmad, I., Lavallée, C., Qvarnstrom, Y., and Dufresne, S. F. (2016). Successful Treatment of Disseminated Annacalia Algerae Microsporidal Infection With Combination Fumagillin and Albendazole. Open Forum Infect. Dis. 3 (3), ofw158. doi: 10.1093/ofid/ofw158

Buppajarntham, A., Atikanukul, T., Putaporntip, C., Jongwutiwes, S., and Suankratay, C. (2021). Myositis Caused by Trachipleistophora Hominis in a Person With Human Immunodeficiency Virus: The First Case in Thailand. Open Forum Infect. Dis. 8 (12), ofab494. doi: 10.1093/ofid/ofab494

Burnham, A. J. (2019). Scientific Advances in Controlling Nosema Ceranae (Microsporidia) Infections in Honey Bees (Apis Mellifera). Front. Vet. Sci. 6 (79), 79. doi: 10.3389/fvets.2019.00079
Seatamanoch et al. Microsporidia Expansion to Humans

Undeen, A. H., and Alger, N. E. (1976). Nosema Algerae: Infection of the White Mouse by a Mosquito Parasite. Exp. Parasitol. 40 (1), 86–88. doi: 10.1016/0014-4894(76)90068-0

Valenčáková, A., and Sučík, M. (2020). Alternatives in Molecular Diagnostics of Encephalitozoon and Enteroctytozoon Infections. J. Fungi 6, 3, 114. doi: 10.3390/jof6030114

van de Straat, B., Sebayang, B., Grigg, M. J., Staunton, K., Garjito, T. A., Vythilingam, I., et al. (2022). Zoonotic Malaria Transmission and Land Use Change in Southeast Asia: What is Known About the Vectors. Malar J. 21 (1), 109. doi: 10.1186/s12936-022-04129-2

Vávra, J., and Lukeš, J. (2013). “Chapter Four - Microsporida and “The Art of Living Together,” in Advances in Parasitology. Ed. D. Rollinson (UK: Academic Press), 253–319.

Visvesvara, G. S. (2002). In Vitro Cultivation of Microsporidia of Clinical Importance. Clin. Microbiol. Rev. 15 (3), 401–413. doi: 10.1128/cmrr.15.3.401-413.2002

Visvesvara, G. S., Belloso, M., Moura, H., Da Silva, A. J., Moura, I. N., Leitch, G. J., et al. (1999). Isolation of Nosema Algerae From the Cornea of an Immunocompetent Patient. J. Eukaryot. Microbiol. 46 (5), 10s.

Wadi, L., and Reinke, A. W. (2020). Evolution of Microsporidia: An Extremely Successful Group of Eukaryotic Intracellular Parasites. PloS Pathog. 16 (2), e1008276. doi: 10.1371/journal.ppat.1008276

Watson, A. K., Williams, T. A., Williams, B. A., Moore, K. A., Hirt, R. P., and Embley, T. M. (2002). A Mitochondrial Remnant in the Microsporidian Trachipleistophora Hominis. Nature 418 (6900), 865–869. doi: 10.1038/nature00949

Yachnis, A. T., Berg, J., Martinez-Salazar, A., Bender, B. S., Diaz, L., Rojiani, A. M., et al. (1996). Disseminated Microsporidiosis Especially Infecting the Brain, Heart, and Kidneys: Report of a Newly Recognized Pansporoblastic Species in Two Symptomatic AIDS Patients. Am. J. Clin. Pathol. 106 (4), 535–543. doi: 10.1093/ajcp/106.4.535

Zhang, G., Sachse, M., Prevost, M. C., Luallen, R. J., Troemel, E. R., and Félix, M. A. (2016). A Large Collection of Novel Nematode-Infecting Microsporidia and Their Diverse Interactions With Caenorhabditis Elegans and Other Related Nematodes. PloS Pathog. 12 (12), e1006093. doi: 10.1371/journal.ppat.1006093

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Seatamanoch, Kongdachalert, Sunantaraporn, Siriyaatien and Brownell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.